Allergan, Plc

This article is about the company known as Allergan, Plc. For the company which was acquired by Actavis, Plc, see Allergan, Inc.

Allergan, Plc

Type	Public
Traded as	NYSE: AGN S&P 500 Component
Industry	Branded and generic pharmaceuticals, and pharmaceutical research and development.
Founded	Est 2015 through the acquisition of Allergan, Inc by Actavis, Plc
Founder	Allen Chao, Ph.D. and David Hsia, Ph.D.
Headquarters	Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States.
Number of locations	40 manufacturing facilities, 27 global R&D centers and marketing/sales facilities worldwide.
Area served	~100 countries
Key people	Paul Bisaro, Executive Chairman, Brenton L. Saunders President and CEO
Products	Branded and generic pharmaceuticals
Revenue	US$ 4.2 billion(Q1 2015)
Operating income	US$ 1.090 billion (2014)
Net income	-US$ 1.630 billion (2014)
Total assets	US$ 52.529 billion (2014)
Total equity	US$ 28.3355 billion (2014)
Number of employees	30,000 (June 2015)
Website	www.allergan.com

On February 18, 2015, the company formerly known as Actavis, Plc announced its intention to change its name to Allergan, Plc. This was completed as of June 15, 2015. Actavis, Plc then became Actavis which now forms the US Generics division of the company.

Corporate history

2015

After the acquisition of Allergan, Inc by Actavis, Plc, the new company made its first acquisition on July 6, when the company acquired start-up, Oculeve, for $125 million. On July 7 the company announced it would acquire Merck & Cos late stage CGRP migraine portfolio, as well as two experimental drugs (MK-1602 and MK-8031) for $250 million. In July, Allergan agreed to sell off its small molecule generic drug business, Actavis, to Teva Pharmaceutical Industries for $40.5 billion ($33.75 billion in cash and $6.75 billion worth of shares), a transaction to be completed in Q1 2016. A day later, the company announced it would acquire Naurex Inc for $560 million with more tied to regulatory milestones. In September the company announced it would acquire ophthalmic device start-up AqueSys for $300 million plus future sums tied to approval/sales milestones. In November the company acquired aesthetic device company Northwood Medical Innovation. Two days after announcing the record breaking deal with Pfizer, the company announced it would partner with Rugen Therapeutic to develop new therapies for autism spectrum disorder and obsessive compulsive disorder.

Pfizer

Main article: Pfizer § Allergan

In late October The Wall Street Journal reported that merger talks between Allergan and Pfizer were in early phases, with Pfizer approaching Allergan due to an industry-wide drop in share prices. Any merger with Allergan would then also give Pfizer the ability to re-domicile to Ireland, taking advantage of its lower tax rates. On 23 November, 2015, the two companies announced their intention to merge for an approximate sum of $160 billion making this the largest pharmaceutical deal ever and the third largest merger in history. As part of the deal, Pfizer CEO Ian Read will remain CEO and Chairman of the combined company (to be called Pfizer Plc), with Allergan CEO, Brent Saunders, becoming President and Chief operating officer. As part of the deal Allergan shareholders will receive 11.3 shares of the company, with Pfizer shareholders receiving one.Pfizer discontinued the acquisition on 5th April 2016, after the Obama administration announced its plan to move ahead with a resolution banning this form of tax avoidance. Pfizer will pay Allergan a breakup fee of $150 million.

2016: Post Pfizer

In April, the company announced it would join Heptares Therapeutics in a deal valued up-to-$3.3 billion collaborating on the development of a subtype-selective muscarinic receptor agonists for Alzheimer's disease and other major neurological disorders. Later in the same month the company announced it would acquire Topokine Therapeutics for $85 million (plus undisclosed milestone payments), gaining the phase IIb/III compound XAF5 - a potential first-in-class treatment for steatoblepharon or bags under the eyes.

Company evolution

Allergan, inc acquisition and Actavis, plc name change

In November 2014 Actavis, plc announced its intention to acquire Allergan, inc, the manufacturer of Botox Completion of the deal would increase its market capitalization to $147 billion. On March 17, 2015, Actavis, plc completed the acquisition of Allergan, inc in a cash and equity transaction valued at approximately $70.5 billion. The combination created a $23 billion diversified global pharmaceutical company with commercial reach across 100 countries. In June 2015, Actavis, plc officially changed its name to Allergan, plc.

Allergan, plc (formerly known as Actavis until June 2015 when it adopted Allergans name.)

Actavis Auden Mckenzie Holdings Limited (Acq 2015 by Actavis) Durata Therapeutics (Acq 2014 by Actavis)   Forest Laboratories (Acq 2014 by Actavis) Furiex Pharmaceuticals Inc (Acq 2014 by Forest) Aptalis Pharma (Eurand Pharmaceuticals & Axcan Pharma merged 2011, Acq 2014 by Forest)   Galen (Acq 2013 by Actavis) Warner Chilcott Plc (Acq 2000 by Galen, adopted Warners name) Procter & Gamble's prescription drug unit (Acq 2009 by Warner)   Watson Pharmaceuticals Andrx Corporation (Acq 2006 by Watson)   Arrow Group (Acq 2009 by Watson)   Eden Biodesign (Acq by Watson)   Specifar Pharmaceuticals S.A. (Acq 2011 by Watson)   Ascent Pharmahealth Ltd (Acq 2012 by Watson)   Actavis Group (Acq 2012 by Watson, adopted Actavis' name) Allergan, inc Kythera Biopharmaceuticals (Acq 2015) MAP Pharmaceuticals Inc (Acq 2013) Inamed Corporation (Acq 2006) Allergan (Advanced Medical Optics spun off in 2006) Actavis (Sold 2015 to Teva Pharmaceuticals) Naurex Inc (Acq 2015) AqueSys (Acq 2015) Topokine Therapeutics (Acq 2016)

Key products

2